Response Genetics (RGDX) 0.52 $RGDX
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium 2015
GlobeNewswire - Thu Jan 15, 1:10PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that the company will present two abstracts at the upcoming American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, CA, January 15 to 17, 2015. One presentation, entitled "Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients" demonstrates the clinical utility of Response Genetics' proprietary ResponseDX KRAS and NRAS mutation detection tests in colorectal cancer. The other presentation, entitled "EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese patients with metastatic colorectal cancer harboring overexpressed EGFR and KRAS exon 2 wild-type treated with cetuximab plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)" provides further clinical evidence for the company's patented ERCC1 mRNA expression technology in predicting response to chemotherapy.
RGDX: 0.52 (+0.06)
Update: Despite A Turnaround, Response Genetics Faces Nasdaq Delisting
Christopher F. Davis - at Seeking Alpha - Fri Dec 26, 10:44AM CST
RGDX: 0.52 (+0.06)
Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber
PR Newswire - Fri Dec 12, 8:00AM CST
Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the Company's Board of Directors, bringing the total number of directors to eight, seven of whom are independent.
RGDX: 0.52 (+0.06), AMRI: 16.94 (-0.28), VRML: 2.08 (+0.12)
Response Genetics Will See Record Revenues In 2015 On The Back Of New York State Approval
Christopher F. Davis - at Seeking Alpha - Thu Dec 11, 9:19AM CST
RGDX: 0.52 (+0.06)
Response Genetics Secures New York State Department of Health Approval for the Company's ResponseDX(R) Testing Services
GlobeNewswire - Thu Dec 11, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, received approval from the New York State Department of Health to offer, market and report results of the Company's ResponseDX tests to healthcare providers in the State of New York. The State of New York is the third most populated state in the U.S. and the addition of this license should contribute to the continued growth of the Company's ResponseDX sales in 2015.
RGDX: 0.52 (+0.06)
N-of-One Expands Executive Team to Meet Market Demand
Business Wire - Tue Dec 09, 12:00PM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced the appointment of two senior executives to support the company's rapid growth. The market for N-of-One's clinical interpretation is exploding, as evidenced by the significant number of new contracts N-of-One signed with major diagnostics companies and leading cancer centers in the past 12 months. In order to proactively support current and prospective clients' evolving needs in precision medicine, the company has created two new positions: Vice President of Sales and Vice President of Operations.
RGDX: 0.52 (+0.06)
Response Genetics Is Priced To Perish; Consider Before 2 Pending Catalysts
Christopher F. Davis - at Seeking Alpha - Sat Nov 29, 9:48AM CST
RGDX: 0.52 (+0.06)
Response Genetics' Quarter: I Think Retail Investors Are Overreacting And I'm Gladly Buying
Christopher F. Davis - at Seeking Alpha - Thu Nov 13, 11:54AM CST
RGDX: 0.52 (+0.06)
Response Genetics ups revenues 10% in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:49AM CST
RGDX: 0.52 (+0.06)
Response Genetics' (RGDX) CEO Thomas Bologna on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:31AM CST
RGDX: 0.52 (+0.06)
Response Genetics EPS of -$0.09
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:03AM CST
RGDX: 0.52 (+0.06)
Response Genetics, Inc. Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the third quarter ended September 30, 2014.
RGDX: 0.52 (+0.06)
Response Genetics reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:38PM CST
RGDX: 0.52 (+0.06)
Response Genetics, Inc. to Release Third Quarter 2014 Financial Results and Host Conference Call on November 13, 2014
GlobeNewswire - Thu Nov 06, 12:03PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its third quarter 2014 financial results and give an operational update in a press release to be issued before the market opens on Thursday, November 13, 2014. The company will host a conference call that same day at 8:30 a.m. EST to discuss its financial results.
RGDX: 0.52 (+0.06)
VRS, DAG, MHLD, RGDX, MVG, PWRD Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Oct 14, 4:01AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Verso Paper Corp (NYSE:VRS), PWRSHS DB AGRI DOUBLE LONG (NYSE
AG), Maiden Holdings Ltd (NASDAQ:MHLD), Response Genetics Inc (NASDAQ:RGDX), MAG SILVER CORP (NYSE:MVG), Perfect World Co Ltd (NASDAQ
WRD) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
MVG: 6.94 (-0.03), DAG: 4.69 (+0.06), MHLD: 13.89 (+0.11), RGDX: 0.52 (+0.06), VRS: 2.23 (unch), PWRD: 18.95 (+0.02)
Response Genetics Combines Cost-Effective, Rapid Turnaround Time With Next Generation Sequencing in Novel Lung Testing Offering
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has launched a new and innovative Non-Small Cell Lung Cancer Profile that merges rapid turnaround on National Comprehensive Cancer Network (NCCN) guideline markers with next-generation sequencing (NGS). This new reflex, or sequential, testing program offers oncologists and pathologists a cost-effective way to utilize comprehensive cancer testing, including NGS, as a reflex-testing option for those patients who test negative for EGFR, ALK and ROS1, the biomarkers recommended by the NCCN.
RGDX: 0.52 (+0.06)
VG, NOA, RGDX, BOFI, DSCI, DNDN Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vonage Holdings Corp (NYSE:VG), North American Energy Partners Inc (NYSE:NOA), Response Genetics Inc (NASDAQ:RGDX), BofI Holding Inc (NASDAQ:BOFI), Derma Sciences Inc (NASDAQ SCI), Dendreon Corp (NASDAQ NDN) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
DSCI: 8.90 (+0.02), BOFI: 91.39 (-0.92), NOA: 3.04 (+0.14), DNDN: 0.13 (-0.02), RGDX: 0.52 (+0.06), VG: 4.37 (+0.02)
Response Genetics selected as molecular screening centre for ALCHEMIST for early-stage lung cancer
M2 - Tue Aug 19, 10:54AM CDT
Molecular diagnostic company Response Genetics (NasdaqCM:RGDX) revealed on Monday the receipt of a research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST).
RGDX: 0.52 (+0.06)
Response Genetics, Inc. to Serve as the Molecular Screening Center for ALCHEMIST
GlobeNewswire - Mon Aug 18, 12:15PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has been awarded a multi-million dollar research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST). ALCHEMIST consists of 3 integrated precision medicine trials that are being implemented through the National Clinical Trials Network (NCTN) of the National Cancer Institute (NCI) - a screening trial and two associated treatment trials.
RGDX: 0.52 (+0.06)
Response Genetics, Inc. Announces Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2014.
RGDX: 0.52 (+0.06)
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium 2015
GlobeNewswire - Thu Jan 15, 1:10PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that the company will present two abstracts at the upcoming American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, CA, January 15 to 17, 2015. One presentation, entitled "Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients" demonstrates the clinical utility of Response Genetics' proprietary ResponseDX KRAS and NRAS mutation detection tests in colorectal cancer. The other presentation, entitled "EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese patients with metastatic colorectal cancer harboring overexpressed EGFR and KRAS exon 2 wild-type treated with cetuximab plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)" provides further clinical evidence for the company's patented ERCC1 mRNA expression technology in predicting response to chemotherapy.
RGDX: 0.52 (+0.06)
Update: Despite A Turnaround, Response Genetics Faces Nasdaq Delisting
Christopher F. Davis - at Seeking Alpha - Fri Dec 26, 10:44AM CST
RGDX: 0.52 (+0.06)
Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber
PR Newswire - Fri Dec 12, 8:00AM CST
Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the Company's Board of Directors, bringing the total number of directors to eight, seven of whom are independent.
RGDX: 0.52 (+0.06), AMRI: 16.94 (-0.28), VRML: 2.08 (+0.12)
Response Genetics Will See Record Revenues In 2015 On The Back Of New York State Approval
Christopher F. Davis - at Seeking Alpha - Thu Dec 11, 9:19AM CST
RGDX: 0.52 (+0.06)
Response Genetics Secures New York State Department of Health Approval for the Company's ResponseDX(R) Testing Services
GlobeNewswire - Thu Dec 11, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, received approval from the New York State Department of Health to offer, market and report results of the Company's ResponseDX tests to healthcare providers in the State of New York. The State of New York is the third most populated state in the U.S. and the addition of this license should contribute to the continued growth of the Company's ResponseDX sales in 2015.
RGDX: 0.52 (+0.06)
N-of-One Expands Executive Team to Meet Market Demand
Business Wire - Tue Dec 09, 12:00PM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced the appointment of two senior executives to support the company's rapid growth. The market for N-of-One's clinical interpretation is exploding, as evidenced by the significant number of new contracts N-of-One signed with major diagnostics companies and leading cancer centers in the past 12 months. In order to proactively support current and prospective clients' evolving needs in precision medicine, the company has created two new positions: Vice President of Sales and Vice President of Operations.
RGDX: 0.52 (+0.06)
Response Genetics Is Priced To Perish; Consider Before 2 Pending Catalysts
Christopher F. Davis - at Seeking Alpha - Sat Nov 29, 9:48AM CST
RGDX: 0.52 (+0.06)
Response Genetics' Quarter: I Think Retail Investors Are Overreacting And I'm Gladly Buying
Christopher F. Davis - at Seeking Alpha - Thu Nov 13, 11:54AM CST
RGDX: 0.52 (+0.06)
Response Genetics ups revenues 10% in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:49AM CST
RGDX: 0.52 (+0.06)
Response Genetics' (RGDX) CEO Thomas Bologna on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:31AM CST
RGDX: 0.52 (+0.06)
Response Genetics EPS of -$0.09
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:03AM CST
RGDX: 0.52 (+0.06)
Response Genetics, Inc. Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the third quarter ended September 30, 2014.
RGDX: 0.52 (+0.06)
Response Genetics reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:38PM CST
RGDX: 0.52 (+0.06)
Response Genetics, Inc. to Release Third Quarter 2014 Financial Results and Host Conference Call on November 13, 2014
GlobeNewswire - Thu Nov 06, 12:03PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its third quarter 2014 financial results and give an operational update in a press release to be issued before the market opens on Thursday, November 13, 2014. The company will host a conference call that same day at 8:30 a.m. EST to discuss its financial results.
RGDX: 0.52 (+0.06)
VRS, DAG, MHLD, RGDX, MVG, PWRD Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Oct 14, 4:01AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Verso Paper Corp (NYSE:VRS), PWRSHS DB AGRI DOUBLE LONG (NYSE
AG), Maiden Holdings Ltd (NASDAQ:MHLD), Response Genetics Inc (NASDAQ:RGDX), MAG SILVER CORP (NYSE:MVG), Perfect World Co Ltd (NASDAQ WRD) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: MVG: 6.94 (-0.03), DAG: 4.69 (+0.06), MHLD: 13.89 (+0.11), RGDX: 0.52 (+0.06), VRS: 2.23 (unch), PWRD: 18.95 (+0.02)
Response Genetics Combines Cost-Effective, Rapid Turnaround Time With Next Generation Sequencing in Novel Lung Testing Offering
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has launched a new and innovative Non-Small Cell Lung Cancer Profile that merges rapid turnaround on National Comprehensive Cancer Network (NCCN) guideline markers with next-generation sequencing (NGS). This new reflex, or sequential, testing program offers oncologists and pathologists a cost-effective way to utilize comprehensive cancer testing, including NGS, as a reflex-testing option for those patients who test negative for EGFR, ALK and ROS1, the biomarkers recommended by the NCCN.
RGDX: 0.52 (+0.06)
VG, NOA, RGDX, BOFI, DSCI, DNDN Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vonage Holdings Corp (NYSE:VG), North American Energy Partners Inc (NYSE:NOA), Response Genetics Inc (NASDAQ:RGDX), BofI Holding Inc (NASDAQ:BOFI), Derma Sciences Inc (NASDAQ
SCI), Dendreon Corp (NASDAQ NDN) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: DSCI: 8.90 (+0.02), BOFI: 91.39 (-0.92), NOA: 3.04 (+0.14), DNDN: 0.13 (-0.02), RGDX: 0.52 (+0.06), VG: 4.37 (+0.02)
Response Genetics selected as molecular screening centre for ALCHEMIST for early-stage lung cancer
M2 - Tue Aug 19, 10:54AM CDT
Molecular diagnostic company Response Genetics (NasdaqCM:RGDX) revealed on Monday the receipt of a research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST).
RGDX: 0.52 (+0.06)
Response Genetics, Inc. to Serve as the Molecular Screening Center for ALCHEMIST
GlobeNewswire - Mon Aug 18, 12:15PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has been awarded a multi-million dollar research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST). ALCHEMIST consists of 3 integrated precision medicine trials that are being implemented through the National Clinical Trials Network (NCTN) of the National Cancer Institute (NCI) - a screening trial and two associated treatment trials.
RGDX: 0.52 (+0.06)
Response Genetics, Inc. Announces Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2014.
RGDX: 0.52 (+0.06)
